European Companies Search Engine
EU funding (€5,948,903): BEhavioral and Adherence Model for improving quality, health outcomes and cost-Effectiveness of healthcaRe Hor1 Sept 2021 EU Research and Innovation programme "Horizon"
Text
BEhavioral and Adherence Model for improving quality, health outcomes and cost-Effectiveness of healthcaRe
The main objective of the Project is to create BEAMER, a disease-agnostic behavioral and adherence model for improving quality, health outcomes and cost-effectiveness of healthcare, through improving the quality of life of individuals, enhance healthcare accessibility and sustainability. The model will allow for tailoring to individual?s needs, using Real World Data captured from patients? behaviors and health system information, transforming the way healthcare stakeholders engage with patients to optimize understanding of their condition and adherence levels throughout their patient journey. BEAMER is driven by a set of Ontology, Epistemology and Methodology principles, supported by Artificial Intelligence, Natural Language Processing, and Machine Learning. BEAMER will optimize the disease-agnostic adherence model by real-life testing proof-of-concept in 18 different pilots in Norway, Spain, the Netherlands, Germany, Portugal, and Italy, including over 18,000 patients (3000 patients in each thematic area). BEAMER will be embodied in an open source European searchable database, continuously updated, validated and optimized by empirical evidence and new insights, available to all stakeholders and adaptable for future developments in healthcare. Finally, extensive efforts will be directed to develop and implement dissemination and communication activities that increase exploitation and sustainability of BEAMER.
Funded Companies:
| Company name | Funding amount |
| €255,938 | |
| Akershus Universitetssykehus HF | €516,875 |
| Astellas Pharma Europe B.V. | €0.00 |
| €202,500 | |
| EMPIRICA GESELLSCHAFT für KOMMUNIKATIONS UND TECHNOLOGIEFORSCHUNG mbH | €346,250 |
| €401,563 | |
| €220,625 | |
| €40,938 | |
| €0.00 | |
| Fundacion para La Investigacion e Innovacion Biosanitaria de Atencion Primaria | €0.00 |
| HEINRICH-HEINE-UNIVERSITAET DUESSELDORF | €286,875 |
| Innovation Sprint | €343,750 |
| Janssen Pharmaceutica N.V. | €0.00 |
| €25,938 | |
| €0.00 | |
| €176,250 | |
| MERCK KGaA | €0.00 |
| Mysphera SL | €231,750 |
| Novo Nordisk A/S | €0.00 |
| €63,340 | |
| Pfizer Ltd. | €0.00 |
| Predictby Research AND Consulting SL | €631,223 |
| €239,062 | |
| Servier Affaires Medicales | €0.00 |
| €266,406 | |
| TAKEDA PHARMACEUTICALS INTERNATIONAL AG | €0.00 |
| Tilburg University- Universiteit Van Tilburg | €422,813 |
| €260,625 | |
| €123,997 | |
| Universidad Politecnica de Madrid | €450,625 |
| Universitetet I Oslo | €441,563 |
Source: https://cordis.europa.eu/project/id/101034369
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "ASSOCIACAO PROTECTORA DOS DIABETICOS DE PORTUGAL - EU funding (€5,948,903): BEhavioral and Adherence Model for improving quality, health outcomes and cost-Effectiveness of healthcaRe"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
